VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-2.91%)
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
VivoSim Labs profit margin
Profit margin (net margin) is net income as a percentage of revenue.
VivoSim Labs's profit margin for the twelve months ending Jun 30, 2026 was -11016.1%. For fiscal 2026 it was -10567.2%, against -1727.8% the year before. The highest annual figure on record is -756.1% in fiscal 2018.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -10567.2% | −8839.4 |
| FY2025 | Mar 31, 2025 | -1727.8% | +11731.9 |
| FY2024 | Mar 31, 2024 | -13459.6% | −8795.0 |
| FY2023 | Mar 31, 2023 | -4664.6% | −3901.4 |
| FY2022 | Mar 31, 2022 | -763.2% | +88.8 |
| FY2020 | Mar 31, 2020 | -852.0% | +9.7 |
| FY2019 | Mar 31, 2019 | -861.7% | −105.6 |
| FY2018 | Mar 31, 2018 | -756.1% | +152.8 |
| FY2017 | Mar 31, 2017 | -908.9% | +1692.2 |
| FY2016 | Mar 31, 2016 | -2601.1% | +2667.2 |
| FY2015 | Mar 31, 2015 | -5268.3% | −1629.8 |
| FY2012 | Dec 31, 2012 | -3638.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -7433.3% | +250.5 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -14410.0% | −27845.3 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -10350.0% | +4012.5 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -9089.3% | −592.6 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -7683.8% | +890.6 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 13435.3% | +23935.3 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -14362.5% | +57717.5 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -8496.7% | −3126.0 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -8574.4% | −3970.0 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -10500.0% | −8008.4 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -72080.0% | −67767.0 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -5370.7% | −5243.3 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -4604.3% | −3473.4 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -2491.6% | −1979.9 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -4313.0% | −3366.4 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -127.4% | +899.5 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -1130.9% | −309.4 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -511.7% | +107.3 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -946.6% | +129.8 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -1026.9% | −352.8 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -821.4% | −145.7 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -619.0% | +79.2 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -1076.3% | −55.9 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -674.1% | +638.3 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -675.7% | +156.7 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -698.2% | −12.0 |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -1020.4% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -1312.4% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -832.4% | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -686.2% | – |
See a number that looks wrong?